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Background: Although the presence of Carbapenemase-producing Enterobacteriaceae (CPE) are extensively
documented in North and South America. CPE have not been reported from Curacao. However, recently intercontinental
spread was suggested of a KPC carbapenemase producing Klebsiella pneumoniae in a patient in the United Kingdom
with previous admission to a hospital in Curacao in 2009.
Findings: After the introduction of the CLSI 2010 revised breakpoints, seven patients with carbapenemase-producing
Enterobacteriaceae were found in a general hospital in Curacao over a period of 16 months. Four patients carried KPC-2
positive Klebsiella pneumoniae, ST11. Two patients carried KPC-3 positive Klebsiella pneumoniae ST258 and one patient
carried a KPC-3 positive Citrobacter freundii. Furthermore, our Klebsiella pneumoniae KPC-2 ST11 strain was matched to
the Klebsiella pneumoniae KPC-2 ST11 strain in the United Kingdom.
Conclusions: Introduction of new laboratory methods, and adoption of new guidelines and breakpoints led to the first
detection of CPE in Curacao. By matching our Klebsiella pneumoniae KPC-2 ST11 strain to a Klebsiella pneumoniae
KPC-2 ST11 strain in the United Kingdom, we suggest that carbapenemase-producing Enterobacteriaceae are
probably more prevalent in Curacao than previously recognized.
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Infections with carbapenemase-producing Enterobacteria-
ceae (CPE) present clinicians with serious treatment chal-
lenges due to limited antibiotic options. They have been
associated with high rates of mortality and morbidity, par-
ticularly in patients with severe underlying illnesses. The
detection of CPE by routine susceptibility testing can be
challenging, since the presence of carbapenem resistance
genes does not always result in high-level resistance to
carbapenems. More and more examples of patients with
unrecognized CPE colonization are reported: these pa-
tients serve as reservoirs for transmission during health* Correspondence: sandra.erkens@mumc.nl
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article, unless otherwise stated.care associated outbreaks, proving the need for rapid and
adequate detection of CPE [1].
Several types of acquired carbapenemases have been
detected in CPE, of which KPC, VIM, IMP, NDM and
OXA-48-like enzymes are most prevalent. Since the de-
tection of the first KPC isolate in 1996 in the United
States [2] CPE have become widely distributed through-
out the world including South America [3]. Until 2010 no
CPE had been reported in Curacao, although intercontin-
ental spread was suggested in a report of a KPC-producing
Klebsiella pneumoniae isolated from a patient in the
United Kingdom who had travelled to Curacao in 2009
[4]. Here we describe the occurrence of carbapenemase-
producing Enterobacteriaceae in Curacao after the intro-
duction of the Clinical and Laboratory Standards Institute
(CLSI) 2010 revised breakpoints.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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St. Elisabeth Hospital in Willemstad, Curacao, is a 355-bed
general hospital, providing care to patients from Curacao,
and other islands of the Netherlands Antilles. It has four-
teen general wards, a 6-bed coronary care unit and a 7-bed
intensive care unit. The number of patient beds per room
and presence of facilities such as bathroom and toilet dif-
fers between first, second and third class rooms. In first
class patients have a private room with a private bathroom
and toilet. Second class rooms are 2–4 bed rooms with the
common use of bathroom and toilet. In third class there
are 6–15 beds per room with the common use of bath-
room and toilet.
All clinical samples are sent to the Analytic Diagnostic
Centre for bacterial culture. Routine identification and
susceptibility testing including detection of carbapene-
mases was according to CLSI standards using VITEK-1
until replacement by a VITEK-2 system in March 2010.
With VITEK-2 lower screening breakpoints for the detec-
tion of CPE were introduced [5]. Decreased carbapenem
susceptibility was confirmed by meropenem E-test and
The modified Hodge test was performed.
From March 2010 - July 2011, all isolates with confirmed
decreased susceptibility to carbapenems were sent to the
Department of Medical Microbiology, Radboud University
Medical Centre in the Netherlands. Confirmation of
species identification was done by MALDI-TOF. Pheno-
typic investigations for carbapenemases included inhib-
ition tests with 3-aminophenylboronic acid, clavulanic
acid and EDTA. Based on the phenotype PCR for blaKPC
genes was performed and amplicons were sequenced.
The presence of extended-spectrum beta-lactamase (ESBL)
and AmpC genes was investigated by Check-MDR CT101
microarray (Check-Points, Wageningen, The Netherlands).
Genotyping of isolates was performed using pulsed-field
gel electrophoresis (PFGE) and multi-locus sequence typ-
ing (MLST) [6].
A K. pneumoniae strain isolated in the UK and suggest-
ive of intercontinental spread from Curacao to the UK
was also investigated [4].Table 1 Details of patients from whom carbapenemase-produ
Patient ID Gender Age
(years)
Date of
positive
culture
Culture site Species
1 M 58 6/5/10 Rectal surveillance K. pneumoniae
2 M 73 13/7/10 Urine K. pneumoniae
3 M 15 24/8/10 Urine K. pneumoniae
4 M 77 26/10/10 Urine K. pneumoniae
5 M 78 9/12/10 Rectal surveillance K. pneumoniae
6 M 68 17/1/11 Wound C. freundii
7 M 64 18/6/11 Wound K. pneumoniae
ND: not determined.Ethical considerations
This study is performed on routine clinical bacterial isolates
and did not require the agreement of the ethical committee
of our institution.Results
In May 2010 the first carbapenemase-producing K. pneu-
moniae was detected from St. Elisabeth Hospital, Curacao.
From May 2010 - July 2011, a total of seven clinical iso-
lates were identified as CPE: six K. pneumoniae and one
Citrobacter freundii. Both blaKPC-2 and blaKPC-3 genes
were detected by PCR and sequencing (Table 1). Merope-
nem MICs ranged from 1 to 32 mg/L. PFGE genotyping
revealed an oligoclonal population of CPE (Figure 1). Four
K. pneumoniae isolates produced KPC-2 carbapenemase,
belonged to ST11 and also produced a CTX-M group 1
ESBL. Two K. pneumoniae isolates with KPC-3 enzymes
belonged to the international ST258 lineage, one of which
also produced an SHV-type ESBL. Besides its chromosomal
AmpC, the C. freundii isolate produced KPC-2 carbapene-
mase, but did not harbour any additional ESBL genes.
The PFGE patterns of the four KPC-2 producing K.
pneumoniae isolates were indistinguishable and were
identical to that of the K. pneumoniae isolate from the
UK, which also produced KPC-2 and belonged to ST11
(Figure 1) [4].Patient information
Five of seven carbapenemase producing Enterobacteria-
ceae were found on third class wards A, B and D, which
are on the ground floor of the hospital. Ward A and B
are localized in the west wing of the hospital. Ward D is
in the east wing of the hospital.
The first K. pneumoniae KPC-3 ST258 discovered in
May, was found in a patient admitted to ward A. This pa-
tient had been transferred from a hospital in Colombia. In
October an identical strain was isolated from a patient in
ward B, but who had previously been admitted to ward A
in May (Table 1).cing Enterobacteriaceae was isolated
Ward Class KPC PFGE MLST MIC
Meropenem
Prior history of
hospital admission
A 3 3 B 258 1 Colombia
B 3 2 A 11 32 -
C 1 2 A 11 2 -
B 3 3 B’ 258 1 Ward A May 2010
D 3 2 A 11 4 -
B 3 3 D ND 1 Ward B Oct. 2010
E 2 2 C 11 8 -
Lane Patient ID PFGE
1
2
3
4
5
6 ’
7
2 A
1 B
3 A
5 A
7 C
4 B
6 D
M   1    2    3    4    5    6    7  UK 
Figure 1 PFGE profiles of seven KPC producing Enterobacteriaceae found in Curacao and the UK isolate. M: marker.
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admitted to ward B at the time of positive culture of the
second patient with KPC-3 K. pneumonia in October.
This patient was screened by the department of Hygiene
Infection Control but found negative at the time.
There was no clustering in the hospital or time between
the four patients with ST11 K. pneumoniae.
Discussion and conclusion
Dissemination of CPE has been described in several differ-
ent countries in South America [7-9]. Results of this study
show that CPE are present among clinical isolates in Curacao
as well. Until then, no CPE had been detected on the island.
However, in March 2010 a new VITEK-2 system was
introduced with the CLSI 2010 revised breakpoints for
Enterobacteriaceae, including the reduced breakpoints for
carbapenem antibiotics. It seems likely that carbapenemase-
producing isolates have been present, but unrecognized
before this update. This is supported by the report of
Virgincar et al. who discussed the nosocomial transmission
of a KPC-2 producing K. pneumoniae ST11 strain in the UK
in 2009, and which was probably introduced by a patient
who had just been discharged from a hospital in Curacao [4].
In our study, the first patient with a KPC-3 producing
K. pneumoniae ST258 had recently been hospitalized in
a hospital in Colombia, where an outbreak with similar or-
ganisms was described 2008 [10]. Since aggressive infec-
tion control has been shown to be effective in controlling
dissemination of CPE, affected patients in our hospital
were placed in contact isolation in single rooms, wherever
possible. Strict compliance to hand hygiene for health care
workers and family was advised by the Department of Hy-
giene Infection Control. However, nosocomial transmis-
sion may have occurred since the second patient with
KPC-3 K. pneumoniae ST258 had been in the same ward
as the first patient. Moreover, a third patient with KPC-3producing C. freundii had been previously admitted to the
same ward as the second patient with KPC-3 K. pneumo-
nia, which may indicate plasmid transfer between species
as well as undetected KPC producers in one of the two or
in both patients.
We have shown that the introduction of new laboratory
methods, and adoption of new guidelines and breakpoints
led to the first detection of CPE in Curacao. We suggest
that carbapenemase-producing Enterobacteriaceae are pos-
sibly more prevalent in Curacao than previously recognized.
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